Physician profile
Kim Pham
NPI 1639444011
$13,113.32
in general payments reported to CMS, 2019-2025
32 companies · $962 in 2025
The $962 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,240 · 2022: $3,733 · 2023: $3,479 · 2024: $1,700 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,140.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,785.42 | 2021-2025 | Haegarda, Hizentra |
| Regeneron Healthcare Solutions, INC. | $1,740.12 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,645.73 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,531.94 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Optinose US, INC. | $732.55 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $638.20 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Grifols USA, LLC | $619.13 | 2021-2024 | Xembify, Prolastin-C Liquid |
| Genzyme Corporation | $578.35 | 2021-2024 | |
| Amgen INC. | $534.69 | 2021-2023 | Tezspire |
| Genentech USA, INC. | $477.37 | 2022-2024 | Xolair |
| Pfizer INC. | $418.13 | 2021-2024 | |
| Kaleo, INC. | $305.88 | 2021-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $282.31 | 2021-2024 | Orladeyo |
| Alcon Vision LLC | $231.44 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $157.43 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $151.16 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $144.22 | 2021-2023 | Ruconest |
| Merck Sharp & Dohme LLC | $140.83 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $132.82 | 2021-2022 | |
| Allergan, INC. | $124.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.07 | 2021-2022 | |
| Octapharma USA, INC. | $120.96 | 2021-2025 | Cutaquig |
| Abbvie INC. | $79.24 | 2022 | |
| Aimmune Therapeutics, INC. | $78.42 | 2021-2022 | |
| Alk-Abello, INC | $69.93 | 2021-2025 | Timothy, Standardized, Standardized Mite D. Farinae, Alternaria Tenuis |
| Blueprint Medicines Corporation | $62.04 | 2024-2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $57.60 | 2022-2024 | Ryaltris |
| Incyte Corporation | $47.23 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $44.74 | 2025 | Neffy |
| Greer Laboratories, INC. | $22.30 | 2024 | Oralair |
| Phadia US INC. | $18.16 | 2022 | |
| Janssen Biotech, INC. | $16.98 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.